Literature DB >> 7579970

Analysis of the structure of naturally processed peptides bound by class I and class II major histocompatibility complex molecules.

E Appella1, E A Padlan, D F Hunt.   

Abstract

Antigen-specific T-cell responses require antigenic peptides presented on the cell surface by the major histocompatibility complex (MHC) molecules. The structural characteristics of these peptides are being defined. It is now known that the majority of peptides that associate with MHC Class I are 8-10 residues long, with allotype-specific binding motifs containing up to three anchor positions. This is consistent with the presence of six pockets and the close-ended structure of the MHC Class I peptide binding groove. In contrast to peptides associated with MHC Class I, those associated with MHC Class II are 10-34 residues in length and are commonly presented in nested sets with extensions or truncations at the N- or C-terminal ends. Binding motifs for MHC Class II appear to contain up to four anchor positions, with more loosely defined amino acid preferences. The expression of histocompatibility proteins in cells that do not load peptides but fold them correctly has permitted the X-ray analysis of the three-dimensional structure of Class I and Class II complexes with single defined peptides. The differences in length between the Class I and Class II sequences can be ascribed to small structural differences between the two binding sites and the positioning of key residues, that make hydrogen bonds to the bound peptides. Recent advances in mass spectrometry are making possible the analysis and sequencing of subpicomolar quantities of MHC-bound peptides and the estimation of the size of the total population of peptides. The sequence information derived from this technique, in conjunction with X-ray crystallographic analysis of MHC complexes involving single, defined peptides, may provide a new approach towards the development of useful reagents for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7579970     DOI: 10.1007/978-3-0348-9061-8_6

Source DB:  PubMed          Journal:  EXS        ISSN: 1023-294X


  10 in total

1.  Definition of Naturally Processed Peptides Reveals Convergent Presentation of Autoantigenic Topoisomerase I Epitopes in Scleroderma.

Authors:  Eleni Tiniakou; Andrea Fava; Zsuzsanna H McMahan; Tara Guhr; Robert N O'Meally; Ami A Shah; Fredrick M Wigley; Robert N Cole; Francesco Boin; Erika Darrah
Journal:  Arthritis Rheumatol       Date:  2020-06-26       Impact factor: 10.995

Review 2.  Designing therapeutic cancer vaccines by mimicking viral infections.

Authors:  Hussein Sultan; Valentyna I Fesenkova; Diane Addis; Aaron E Fan; Takumi Kumai; Juan Wu; Andres M Salazar; Esteban Celis
Journal:  Cancer Immunol Immunother       Date:  2016-04-06       Impact factor: 6.968

Review 3.  Plant systems biology: insights, advances and challenges.

Authors:  Bhavisha P Sheth; Vrinda S Thaker
Journal:  Planta       Date:  2014-03-27       Impact factor: 4.116

Review 4.  Immunogenetics of Disease-Causing Inflammation in Sarcoidosis.

Authors:  Johan Grunewald; Paolo Spagnolo; Jan Wahlström; Anders Eklund
Journal:  Clin Rev Allergy Immunol       Date:  2015-08       Impact factor: 8.667

5.  Characterization of hepatitis E-specific cell-mediated immune response using IFN-gamma ELISPOT assay.

Authors:  M T Shata; A Barrett; N J Shire; S F Abdelwahab; M Sobhy; E Daef; S S El-Kamary; M Hashem; R E Engle; R H Purcell; S U Emerson; G T Strickland; K E Sherman
Journal:  J Immunol Methods       Date:  2007-09-19       Impact factor: 2.303

6.  Development of immune-specific interaction potentials and their application in the multi-agent-system VaccImm.

Authors:  Anna Lena Woelke; Joachim von Eichborn; Manuela S Murgueitio; Catherine L Worth; Filippo Castiglione; Robert Preissner
Journal:  PLoS One       Date:  2011-08-17       Impact factor: 3.240

Review 7.  Emerging vaccine informatics.

Authors:  Yongqun He; Rino Rappuoli; Anne S De Groot; Robert T Chen
Journal:  J Biomed Biotechnol       Date:  2011-06-15

8.  Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo.

Authors:  A L Zarling; S B Ficarro; F M White; J Shabanowitz; D F Hunt; V H Engelhard
Journal:  J Exp Med       Date:  2000-12-18       Impact factor: 14.307

9.  Current challenges in peptide-based drug discovery.

Authors:  Laszlo Otvos; John D Wade
Journal:  Front Chem       Date:  2014-08-08       Impact factor: 5.221

10.  Integration of proteomics, bioinformatics, and systems biology in traumatic brain injury biomarker discovery.

Authors:  J D Guingab-Cagmat; E B Cagmat; R L Hayes; J Anagli
Journal:  Front Neurol       Date:  2013-05-31       Impact factor: 4.003

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.